ABSTRACT Background/aims To investigate the predictive factors for the resolution of retinal fluid after intravitreal injections of ranibizumab (IVRs) for polypoidal choroidal vasculopathy (PCV). Methods Forty-seven eyes of 45 patients with symptomatic PCV received 0.5 mg of IVR monthly for 3 months. One month after the third IVR, the presence of dry macula, defined as absence of retinal fluid as detected by the use of optical coherence tomography, was retrospectively evaluated and correlated with clinical characteristics at baseline. Most of the eyes were followed for over 6 months. Results Of the 47 eyes, 31 eyes (66%) achieved the dry macula along with increased best-corrected visual acuity (BCVA) (0.64 to 0.46 logarithm of the minimum angle of resolution units, p<0.0001), while the other 16 eyes without dry macula showed no significant change of BCVA. Univariate analyses of the baseline characteristics identified the smaller size of the largest polyp (p¼0.0008) and the absence of serous or haemorrhagic pigment epithelial detachment (p¼0.045) as predictive factors for the dry macula. Multivariate logistic regression found the independent predictor for the dry macula to be the smaller size of the largest polyp (p¼0.001). No severe systemic or ocular adverse events were observed. Conclusions IVR may be helpful for resolution of retinal fluid and increased BCVA in the short term, but larger polyps and pigment epithelial detachments at baseline may be negative prognostic factors for a therapeutic response. Further studies are needed to clarify the long-term efficacy of IVR for PCV.
INTRODUCTION
Polypoidal choroidal vasculopathy (PCV) is considered to be one of the subtypes of exudative age-related macular degeneration and is characterised by abnormal branching vascular networks with polypoidal lesions located in the inner choroid. 1e3 Uyama and associates 4 reported the natural progression of PCV eyes, in that 50% of the patients in that study had a favourable course whereas the other half had repeated bleeding and leakage, resulting in macular degeneration and visual loss. Many previous studies have proven the efficacy of photodynamic therapy (PDT) with verteporfin for PCV, with resolution of polyps and associated fluid which led to improvement or stabilisation of visual outcome. 5e15 However, one of the main concerns with PDT is subretinal or subpigment epithelial haemorrhage. 7 12 13 16 In addition, long-term follow-up has shown that the improved or stabilised visual outcome might not be maintained should there be a recurrence of disease activity.
17e19 Therefore, it is important to seek alternative methods for the treatment of PCV.
Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents, specifically, bevacizumab and ranibizumab (Lucentis; Genentech, South San Francisco, California, USA), reportedly demonstrated reduction of exudation from PCV with various visual outcomes. 20e25 However, such agents were not effective for diminishing the abnormal choroidal vasculature itself. Thus, the potential efficacy of anti-VEGF treatment for PCV is still difficult to assess.
It should be noted that there is some rationale for using anti-VEGF treatment for PCV. First, it is known that VEGF is upregulated in the aqueous humour in eyes with PCV. 26 Second, specimens obtained from the eyes with PCV also showed strong expression of VEGF in vascular endothelial cells and retinal pigment epithelium cells. 27 On the other hand, another histopathologic study was unable to identify VEGF in vascular endothelial cells in PCV specimens, although VEGF was still found in the retinal pigment epithelium cells. 28 Therefore, the contribution of VEGF in the pathogenesis of PCV seems to vary among cases. If the clinical characteristics related to the response to anti-VEGF agents before starting treatment of PCV can be fully elucidated, then that might prove helpful for choosing proper treatment strategies.
The purpose of this study was to find the predictive clinical factors for the resolution of retinal fluid from PCV after intravitreal injections of ranibizumab (IVRs) in the short term. We believe that this current study provides additional information for the management of PCV.
MATERIALS AND METHODS
This study included 47 eyes of 45 consecutive cases (35 eyes of 34 males and 12 eyes of 11 females) with symptomatic PCV involving the subfoveal region. The major exclusion criteria were past treatment histories of PCV, previous vitrectomy, cataract surgery within the past 90 days, a history of systemic vascular events such as myocardial infarction or cerebral vascular accidents, and uncontrolled hypertension. All eyes had at least one of the following at baseline: (1) subretinal fluid, (2) intraretinal fluid or (3) subretinal haemorrhages, all of which could be detected by a spectral-domain optical coherence tomography (OCT) (3D OCT1000; TOPCON Corp, Tokyo, Japan). At baseline, all eyes had complete ophthalmic examinations including best-corrected visual acuity (BCVA) testing with Landort C charts, colour fundus photography, and fluorescein angiography (FA) and indocyanine green angiography (ICGA) using a confocal scanning laser ophthalmoscopy (HRA-2; Heidelberg Engineering Inc, Dossenheim, Germany). The diagnosis of PCV was confirmed with characteristic polypoidal vascular lesions and branching choroidal vascular networks revealed by ICGA. 3 Sometimes, PCV lesions could be detected funduscopically by the presence of an orangeered retinal protrusion over the polyps.
All patients received 0.5 mg of IVR monthly for 3 months; at baseline, at 1 month and at 2 months. At 3 months, the frequency of 'dry macula', which was defined as absence of subretinal or intraretinal spaces detected by use of OCT, was investigated. All cases, except for two cases experiencing nausea at the baseline angiography, underwent FA and ICGA at 3 months for follow-up, and the morphologic changes on ICGA were also examined. From that point onward, the patients received additional IVRs according to the discretion of the physicians, or when the patients wished, PDT with verteporfin was administrated as an alternative treatment. Most of the eyes were followed over 6 months. In addition to the biomicroscopic examination, BCVA testing and OCT were performed monthly at every visit.
As for the possible factors that might influence the achievement of dry macula, we considered several factors at baseline. The data consisted of age, gender, BCVA at baseline, the size of choroidal vascular networks on ICGA, the size of the largest polyp, the number of polyps, presence of concurrent type-2 choroidal neovascularisation, presence of choroidal vascular hyperpermeability on ICGA, presence of subretinal fluid and/or intraretinal fluid, presence of lipid deposition, presence of subretinal haemorrhage larger than the area of one optic disc and presence of serous or haemorrhagic pigment epithelial detachment (PED) larger than the area of one optic disc. The size of the largest polyp was determined by careful observation of the ICGA through the early phase to the late phase, which enabled the demarcation of each polyp. All the measurements on ICGA were performed using an electronic caliper within HRA-2.
The obtained data were analysed with frequency and descriptive statistics. BCVA was converted to logarithm of the minimum angle of resolution (logMAR) units before analyses. c 2 testing was used for categorical analysis. The Fisher exact test was used if the expected cell count was fewer than five. Means were compared by use of the ManneWhitney U test. The changes in BCVA were analysed using a paired t test. To model the related factors for the dry macula, logistic regression was performed to adjust for mutual confounding among the covariates tested. Forward stepwise regression using the likelihoodratio method, in which change in the likelihood-ratio statistic was based on the maximum partial likelihood estimates for the covariate, was used for variable selection. All of the statistical analyses were performed with SPSS software V.18.0 (SPSS, Inc.). A p value of <0.05 was considered to be significant, and all tests were two-sided.
The study protocol followed the tenets set forth in the Declaration of Helsinki, and ethics approval was obtained from the Institute Review Board of Kyoto Prefectural University of Medicine. All patients provided written informed consent before receiving IVRs.
RESULTS
The mean age of the 45 patients was 74.8 years (SD: 7.6 years; range: 57e89 years). All 47 eyes showed subretinal and/or intraretinal spaces induced by fluid accumulation or haemorrhage involving the fovea on OCT images at baseline. BCVA at baseline ranged from À0.08 to 1.70 logMAR units (mean: 0.68; median: 0.70).
At 3 months, 31 of the 47 eyes (66%) achieved the dry macula. The mean BCVA of the 47 eyes improved from baseline to 3 months (0.68 to 0.57 logMAR units, p¼0.0046). Of the 47 eyes, 11 eyes (24%) showed increased BCVA of 0.3 or more logMAR units, 33 eyes (70%) maintained baseline BCVA and three eyes (6%) showed decreased BCVA of 0.3 or more logMAR units. Although BCVA at baseline was not significantly different, the eyes with dry macula showed significantly better BCVA with improvement than those without dry macula (figure 1). The eyes without the dry macula did not show significant change of BCVA after treatments.
The results of the univariate analyses are shown in the table 1.
The results of the analyses showed that the factors associated with dry macula were the smaller size of the largest polyp (p¼0.0008) and the absence of PED (p¼0.045). Forward stepwise logistic regression of factors revealed that the smaller size of the largest polyp was the sole factor associated with the dry macula (p¼0.001). At baseline, nine eyes had serous or haemorrhagic PED. Of those nine eyes, PED decreased in four eyes and remained stable in five eyes. A new PED developed in one of the 38 eyes without PED at baseline.
FA and ICGA were able to be performed and evaluated at 3 months in 45 of the 47 eyes. Of those 47 eyes, nine eyes (19%) exhibited complete resolution of polyps, 12 eyes (26%) showed partial regression of polyps and one eye (2%) demonstrated an increased number of polyps compared to the baseline. In the remaining 25 eyes (53%), the polyps were unchanged. Of the nine eyes with complete resolution of polyps, all eyes but one achieved the dry macula. No eyes revealed significant regression of the branching vascular networks.
Twenty-six of 31 eyes with dry macula at 3 months were able to be followed up monthly over a 6-month period. Of those 26 eyes, a mild recurrence of subretinal or intraretinal fluid was seen in 13 eyes (50%): in 10 eyes at 4 months, in one eye at 5 months, and in the other two eyes at 6 months. Of those 13 eyes, additional IVRs were given to 12 eyes according to the discretion of Figure 1 The changes in visual acuity (in logarithm of the minimum angle of resolution (logMAR) units) in eyes with and without dry macula at 3 months. Individual best-corrected visual acuity (BCVA) data are shown as mean BCVA 6SD. The BCVA at baseline was not statistically different between the two groups. After 3 monthly intravitreal injections of ranibizumab, the eyes that achieved a dry macula showed better BCVA with significant gain. the physicians, while PDT was applied on the other one eye at the request of the patient. The remaining 13 eyes (50%) showed no recurrence over 6 months without additional IVRs.
Fifteen of the 16 eyes without dry macula at 3 months were able to be followed up monthly over a 6-month period. Of those 15 eyes, 11 eyes received additional IVRs according to the discretion of the physicians throughout the 6 months, but only one eye achieved temporary resolution of fluid during that period. Of the other four eyes, three eyes underwent PDT and one eye received PDT combined with IVR, at the request of the patients.
During the 6-month observation period, one eye treated with IVR alone developed two disc areas of subretinal haemorrhage at 5 months, but BCVA was not affected. No other systemic or ocular adverse events were observed during that 6-month period. Representative examples from the above-described cases are shown in figures 2 and 3.
DISCUSSION
This study demonstrated that the size of the largest polyp on ICGA and the presence of PED might be a possible factor that predicts the persistent retinal fluid from PCV after monthly IVRs for 3 months by the univariate analyses. Multivariate logistic regression found the independent predictor for the persistent retinal fluid in the macula to be the size of the largest polyp. Previous reports consistently demonstrated that intravitreal injections of bevacizumab or IVRs reduced the fluid from PCV, but did not diminish the abnormal choroidal vasculature itself. 20e25 No previous reports have shown the factors predicting the changes of retinal fluid after IVRs for PCV. The persistent retinal fluid at 3 months rarely resolved in spite of additional IVRs through 6 months, whereas half of the PCV eyes without fluid at 3 months, and that received no additional treatment through the 6-month period, showed no recurrence. Thus, this information may be helpful when physicians consider the optimal treatment for PCV.
Maintaining a normal retinal anatomy without pathologic fluid accumulation is reportedly important for the management of exudative age-related macular degeneration with IVR. 29 30 In this present study, the eyes with dry macula at 3 months showed increased BCVA, while those without dry macula exhibited no significant change in BCVA. Thus, for the treatment of PCV with large polyps and/or PEDs, IVR may actually be less frequently helpful for improving the retinal anatomy and the visual outcome.
Resolution of the polypoidal lesions appears to be directly related to the resolved fluid, as shown by the previous reports using thermal photocoagulation 31 and PDT. 5e15 Our study also demonstrated that eight of the nine eyes that achieved complete resolution of polyps also exhibited a dry macula. Thus, monitoring the morphologic changes on ICGA may also be valuable in the management of PCV with IVR. The rates of complete resolution or decreased number of polyps after one to three intravitreal injections of bevacizumab or IVRs have reportedly ranged from 9% to 80%. 20e25 However, the rate was 45% (complete resolution of polyps in 19% and decreased number of polyps in 26%) in the current study. The reason behind these different resolution rates might be explained by the fact that PCV lesions vary histopathologically among cases. 27 28 32e34 In the discussion in a previous report regarding bevacizumab treatment for PCV, Gomi and associates anticipated that ranibizumab might penetrate more deeply into the choroidal vascular abnormalities and might provide better efficacy for the treatment of PCV, thanks to its smaller molecular weight and higher affinity for VEGF than that of bevacizumab. 21 Our study showed only a moderate effect on diminishing the polyps, similar to the result of 33% that Kokame and associates 23 reported with IVRs. Moreover, the findings of this present study showed that the branching vascular network vessels did not show significant regression after IVRs, as was reported before. 21 23 Previous studies have reported that persistence of the branching vascular networks was also observed in most of the eyes treated with PDT and that the persistence was presumably associated with the recurrence of polyps and resultant exudative changes. 18 19 35 Therefore, future treatment strategies for PCV should include a careful observation of the polyps and the branching vascular networks.
In this present study, we were unable to draw a definitive conclusion as to why PCV with large polyps had a poorer response to IVRs. One possibility is that a 0.5 mg monthly administration of IVRs is an insufficient dosage to suppress vascular hyperpermeability of the large polyps. Song and associates 24 reported the results of administering a single intravitreal injection of 1.25 mg or 2.5 mg bevacizumab in 19 PCV eyes. Although the dose selection in that study was not randomised, they found that there was no significant difference in the changes in central retinal thickness at 3 months between the two doses. At least in the case of bevacizumab, there seemed to be no dramatic response yielded by the escalated dose. Another possible reason might be attributed to the hypothesis that PCV with large polyps may develop with less contribution of VEGF than PCV with small polyps. However, the precise role of VEGF in the pathogenesis of PCV is a question that remains to be investigated.
In this present study, though not strong, the presence of PED at baseline was also statistically significant in univariate analyses for the persistent retinal fluid. Saito and associates 14 applied PDT on eyes with PCV with serous PED and noted anatomic improvement and gain in BCVA at 12 months, and those results were similar to the outcome of eyes without PED. For eyes with PED, further studies are needed to evaluate the long-term benefits and risks of each treatment.
This study has limitations inherent to the retrospective nature and the short follow-up period. In addition, although relatively large compared to the previous reports, the number of patients was too small to draw definite conclusions. Furthermore, the variable treatment decisions after the first 3 months of IVR treatment might be a weaker part of the study design. However, we demonstrated that the size of the largest polyps and the presence of PED might influence the resolution of fluid from PCV. In other words, we found that there is a certain subgroup of PCV eyes showing favourable responses to IVR in the short term. Further studies with longer follow-up are needed to clarify the long-term efficacy of IVR for PCV. 
